We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Biomarker Team Develops Validation Testing of Biomarkers

By Biotechdaily staff writers
Posted on 09 May 2007
A biomarker testing company has formed an expert team to expedite biopharmaceutical customer need for high-throughput assay services.

Covance (Princeton, NJ, USA) has announced that a panel of top scientists will provide technical and scientific expertise for customers in the selection, development, validation, and testing of biomarker assays across the drug development continuum

Through our market research, we have identified a significant need that exists in drug development for high-throughput biomarker development services, said Deborah Tanner, president, Covance central laboratory services. More...
Our biomarker expert team offers decades of experience in biomarker testing and validation, which combined with our high-throughput capabilities will significantly increase the effectiveness and efficiency of our clients' drug development programs. Covance's biomarker expert team will enhance communication on all biomarker-related services while supporting the ongoing testing and validation of biomarker assays, including work on custom biomarker assays.

Covance offers nearly all biomarker-testing needs directly or in collaboration with its qualified referral laboratories. In addition to providing globally the highest throughput of good laboratory practice (GLP) and non-GLP biomarker services from its central laboratory, bioanalytic and toxicology laboratories, Covance offers bioimaging capabilities and cardiac-related biomarkers for both animals and humans.

Clinically useful biomarkers are required to inform therapeutic decision-making regarding candidate drugs and related indications to help bring new medicines to patients faster. Effective use of biomarkers leads to faster decisions to continue or suspend a drug's development, saving pharmaceutical manufacturers money by reducing late stage failures while improving predictability of success.

Pharmaceutical companies are using biomarkers for nearly every new drug candidate, and it is predicted that within the next ten years biomarkers will be a standard aspect of drug development for any novel candidate. The US Food and Drug Administration (FDA) has made biomarkers central to the Critical Path initiative it launched in March 2004 with the aim of modernizing and streamlining medical product development.


Related Links:
Covance

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care

Dementia is the leading cause of death in the UK, accounting for almost one in eight deaths, with more than 72,000 people dying from dementia, including Alzheimer’s disease, in 2025. Despite this burden,... Read more

Microbiology

view channel
Image: Overview of a rapid diagnostic workflow for fungal bloodstream infections (Photo courtesy of Professor Hiroki Takahashi and IMO, Chiba University, Japan)

Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive

Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.